Dashboard
Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.93 times
- Poor long term growth as Net Sales has grown by an annual rate of 14.78% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.93 times
- The company has been able to generate a Return on Equity (avg) of 2.29% signifying low profitability per unit of shareholders funds
Healthy long term growth as Operating profit has grown by an annual rate 40.44%
Positive results in Sep 26
Stock is technically in a Mildly Bullish range
With ROCE of 3.7, it has a Attractive valuation with a 1.2 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
INR 3,346 Cr (Small Cap)
28.00
40
0.00%
0.12
4.23%
1.22
Total Returns (Price + Dividend) 
Latest dividend: 4 per share ex-dividend date: Aug-01-2022
Risk Adjusted Returns v/s 
Returns Beta
News

Unichem Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness
Unichem Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive grade, signalling a positive change in price attractiveness despite a challenging pharmaceutical sector environment. This article analyses the recent valuation changes, compares them with peer averages and historical benchmarks, and assesses the implications for investors.
Read More
Unichem Laboratories Ltd is Rated Hold
Unichem Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 November 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Unichem Laboratories Ltd is Rated Hold by MarketsMOJO
Unichem Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 November 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
05-Nov-2026 | Source : BSEPublication of Financial Results for quarter and half year ended September 30 2026 in newspapers.
Board Meeting Outcome for Results For Q2 FY2027
04-Nov-2026 | Source : BSEUnaudited Financial Statements (Consolidated & Standalone) for the second quarter and half year ended 30th September 2026.
Financial Results For Q2FY27
04-Nov-2026 | Source : BSEUnaudited financial Results for Q2FY2027
Corporate Actions 
No Upcoming Board Meetings
Unichem Laboratories Ltd has declared 200% dividend, ex-date: 01 Aug 22
Unichem Laboratories Ltd has announced 2:5 stock split, ex-date: 21 Oct 10
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 4 Schemes (8.65%)
Held by 48 FIIs (2.7%)
Ipca Laboratories Limited (52.67%)
Hdfc Small Cap Fund (7.04%)
14.9%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 1.20% vs 10.00% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is -46.42% vs 280.11% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 11.59% vs 18.11% in Sep 2024
Growth in half year ended Sep 2025 is -183.75% vs 206.12% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 6.76% vs 16.81% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 186.14% vs 75.93% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 4.31% vs 18.25% in Mar 2025
YoY Growth in year ended Mar 2026 is 83.86% vs 246.67% in Mar 2025